Many employers and insurers are scaling back coverage of Wegovy and Zepbound, and a key government program, Medicare, doesn’t ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...

By: Arnolt Center for Investigative Journalism staff and Leslie Bonilla Muñiz Indiana has poured almost $1 billion into a ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...

Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

The risk for cardiovascular mortality in survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis peaks within ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...